Ngā hua rapu - David T. Teachey

Whakamahine hua
  1. 1
    Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)

    Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS) mā David T. Teachey

    I whakaputaina 2004
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome

    New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome mā David T. Teachey

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Predicting relapse risk in childhood acute lymphoblastic leukaemia

    Predicting relapse risk in childhood acute lymphoblastic leukaemia mā David T. Teachey, Stephen P. Hunger

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Diagnosis and Management of Autoimmune Cytopenias in Childhood

    Diagnosis and Management of Autoimmune Cytopenias in Childhood mā David T. Teachey, Michele P. Lambert

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    T-cell acute lymphoblastic leukemia

    T-cell acute lymphoblastic leukemia mā Elizabeth A. Raetz, David T. Teachey

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Autoimmune lymphoproliferative syndrome: more than a FAScinating disease

    Autoimmune lymphoproliferative syndrome: more than a FAScinating disease mā Karen L. Bride, David T. Teachey

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Pré-impressão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia

    Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia mā David T. Teachey, Ching‐Hon Pui

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children

    How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children mā David T. Teachey, David O’Connor

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

    Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome mā Chelsea Kotch, David M. Barrett, David T. Teachey

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy

    Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy mā Andrew D. Hughes, David T. Teachey, Caroline Diorio

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Toxicity management for patients receiving novel T-cell engaging therapies

    Toxicity management for patients receiving novel T-cell engaging therapies mā David M. Barrett, David T. Teachey, Stephan A. Grupp

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)

    Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) mā David T. Teachey, Alix E. Seif, Stephan A. Grupp

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

    Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies mā David T. Teachey, Stephan A. Grupp, Valerie I. Brown

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies

    Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies mā Sarah K. Tasian, David T. Teachey, Susan R. Rheingold

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Cellular therapy: Immune‐related complications

    Cellular therapy: Immune‐related complications mā Joseph H. Oved, David M. Barrett, David T. Teachey

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia

    Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia mā David T. Teachey, Stephen P. Hunger, Mignon L. Loh

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies

    Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies mā David Barrett, Valerie I. Brown, Stephan A. Grupp, David T. Teachey

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

    CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia mā Shannon L. Maude, David T. Teachey, David L. Porter, Stephan A. Grupp

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

    Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies mā Shannon L. Maude, David M. Barrett, David T. Teachey, Stephan A. Grupp

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'

    Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' mā David T. Teachey, Michael R. Bishop, David G. Maloney, Stephan A. Grupp

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: